Symbols / LABU
LABU Chart
About
The fund, under normal circumstances, invests at least 80% of its net assets in financial instruments, such as swap agreements, securities of the index, and ETFs that track the index, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards ("GICS"). The fund is non-diversified.
Fundamentals
Scroll to Statements| Sector | — | Industry | — | Market Cap | — |
| Enterprise Value | — | Income | — | Sales | — |
| Book/sh | — | Cash/sh | — | Dividend Yield | 81.00% |
| Payout | — | Employees | — | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | — | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | — |
| Current Ratio | — | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | — | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | — | ROA | — |
| ROE | — | ROIC | — | Gross Margin | — |
| Oper. Margin | — | Profit Margin | — | Shs Outstand | — |
| Shs Float | — | Short Float | — | Short Ratio | — |
| Short Interest | — | 52W High | 198.18 | 52W Low | 32.55 |
| Beta | — | Avg Volume | 606.82K | Volume | 347.33K |
| Target Price | — | Recom | — | Prev Close | $179.40 |
| Price | $178.40 | Change | -0.56% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
No analyst ratings or price targets available.
- LABU: The Risks And Rewards Of A Leveraged Biotechnology ETF (NYSEARCA:LABU) - Seeking Alpha Fri, 23 Jan 2026 08
- How (LABU) Movements Inform Risk Allocation Models - Stock Traders Daily ue, 17 Feb 2026 23
- Triple-Leveraged Biotech ETF Doubles as Regulatory Winds Shift in 2026 - 24/7 Wall St. Fri, 16 Jan 2026 08
- Labubus Are All the Rage. They’re Fueling Monster Gains for This Stock. - Barron's hu, 17 Jul 2025 07
- 'Gateway drug': Labubus are getting U.S. consumers hooked on Pop Mart and driving up business - CNBC hu, 31 Jul 2025 07
- How to Trade Biotech’s Volatility with LABU/LABD | CRISPR & Cancer Stocks - ETFguide Mon, 22 Dec 2025 14
- Triple-Leveraged Biotech ETF Doubles as Regulatory Winds Shift in 2026 - AOL.com Fri, 16 Jan 2026 08
- Trading Systems Reacting to (LABU) Volatility - Stock Traders Daily Fri, 06 Feb 2026 08
- The Labubu Viral Sensation Is Now Available at Target - Billboard Mon, 08 Sep 2025 07
- Pop Mart, maker of popular Labubus, opens at Mall of America - Star Tribune Fri, 31 Oct 2025 07
- Has Labubu Craze Peaked? The Celeb Viral Bag Charm Is Suddenly In Stock for Just $20 on Amazon - Variety ue, 07 Oct 2025 07
- StockX and Walmart Restock Sold-Out Labubus After Success of Last Month’s Limited Run - The Hollywood Reporter ue, 23 Sep 2025 07
- Looking for Sold-Out Labubus? StockX and Walmart Are Dropping Hard-to-Find Pop Mart Releases Daily This Week - Rolling Stone Mon, 18 Aug 2025 07
- Could Apple and Labubus Be a Match Made in Heaven? - Business Insider ue, 14 Oct 2025 07
- Pop Mart shares surge 12% after CEO says mini Labubus could launch as soon as this week - New York Post Wed, 20 Aug 2025 07
Insider Transactions
No recent insider transactions.
Financials
No financial statements available. Data is sourced from Yahoo Finance and cached; historical storage may be added later.
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for LABU
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|